{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59"}]}],"title":"Leukocytes, G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"Leukocytes, G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Leukocytes, G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Leukocytes, G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Leukocytes, G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"}]}],"title":"Neutrophils, G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Neutrophils, G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Neutrophils, G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Neutrophils, G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Neutrophils, G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74"}]}],"title":"Hemoglobin (increased), G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Hemoglobin (increased), G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hemoglobin (increased), G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hemoglobin (increased), G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hemoglobin (increased), G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"}]}],"title":"Hemoglobin (anemia), G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"Hemoglobin (anemia), G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Hemoglobin (anemia), G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemoglobin (anemia), G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hemoglobin (anemia), G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47"}]}],"title":"Lymphocytes (increased), G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Lymphocytes (increased), G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}],"title":"Lymphocytes (increased), G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Lymphocytes (increased), G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Lymphocytes (increased), G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"65"}]}],"title":"Lymphocytes (decreased), G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Lymphocytes (decreased), G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Lymphocytes (decreased), G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymphocytes (decreased), G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Lymphocytes (decreased), G4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"Hematology parameters were summarized according to the NCI CTCAE, version 4.0: G0, none, G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: leukocytes, neutrophils, hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), and lymphocytes (decreased). For participants randomized to Placebo in Part 1, the BL value for Part 2 is defined as the value taken at Week 13 of Part 1. For participants randomized to Eltrombopag in Part 1, the BL value is defined as the value taken on Day 1 or, if missing, the latest non-missing Screening value. For participants who do not have both a Screening and Day 1 value, the Screening or Day 1 value will be used as BL. The maximum post-BL toxicity grade includes any scheduled or unscheduled post-BL assessment.","groups":[{"description":"Participants who received eltrombopag in Part 1 continued on the same dose in Part 2 unless adjustments were warranted according to the dosing guidelines. Participants who received placebo in Part 1 received Eltrombopag as per age criteria as follows: aged between 6 and 17 years with a body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD. Participants aged between 1 and 5 years received eltrombopag 1.2 mg/kg QD and; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day.","id":"OG000","title":"Part 2 (Open-Label Period) - Eltrombopag"}],"paramType":"NUMBER","populationDescription":"Safety Population. Only those participants who entered into Part 2 (Open-label eltrombopag-only phase) were analyzed.","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 24 of Part 2 and Follow-up Weeks 1 to 4 (up to Study Week 41)","title":"Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 2","type":"SECONDARY","unitOfMeasure":"Participants"}